GlassScriptPhysician profile
Henry M Rosevear
NPI 1669679460
$3,320.51
in general payments reported to CMS, 2019-2025
32 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $331 · 2021: $368 · 2022: $164 · 2023: $385 · 2024: $448 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806 · Consulting Fee: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.22 |
| Consulting Fee | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $490.17 | 2019-2025 | Xtandi, Myrbetriq |
| Medtronic USA, INC. | $369.56 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $308.89 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $261.60 | 2021-2025 | Lupron Depot |
| Urogen Pharma, INC. | $208.74 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $202.69 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| C. R. Bard, INC. & Subsidiaries | $198.24 | 2020-2022 | |
| Myriad Genetic Laboratories, INC. | $166.31 | 2021-2024 | Prolaris, Myrisk |
| Bioprotect Medical, INC. | $130.13 | 2025 | Bioprotect Balloon Implant System |
| Olympus America INC. | $121.96 | 2025 | Itind System |
| Endo USA, INC. | $109.59 | 2024-2025 | Xiaflex |
| Medtronic, INC. | $99.70 | 2021-2023 | Gia, Interstim |
| Dendreon Pharmaceuticals LLC | $92.50 | 2020-2025 | Provenge |
| Astrazeneca Pharmaceuticals LP | $78.39 | 2019 | |
| Laborie Medical Technologies Corp. | $68.86 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $48.30 | 2022-2023 | Altis |
| Ferring Pharmaceuticals INC. | $44.87 | 2019-2025 | Adstiladrin |
| Allergan, INC. | $37.71 | 2019-2021 | |
| Myovant Sciences INC. | $34.82 | 2021 | |
| Boston Scientific Corporation | $31.27 | 2023 | Spaceoar Vue System - 10ml |
| Janssen Biotech, INC. | $25.63 | 2019 | |
| Axonics, INC. | $22.19 | 2023 | Bulkamid, Axonics |
| Steris Corporation | $20.68 | 2024 | |
| Halozyme INC | $19.98 | 2023 | |
| Bard Access Systems, INC. | $18.95 | 2019 | |
| Angiodynamics, INC. | $18.41 | 2022 | |
| Calyxo, INC. | $17.68 | 2024 | Cvac Aspiration System |
| Tempus Ai, INC | $17.33 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.74 | 2019 | |
| Rochester Medical Corporation | $14.43 | 2021 | |
| Bard Peripheral Vascular, INC. | $13.69 | 2020 | |
| Pfizer INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Rosevear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.